Aralez Pharma (ARLZ) Tops Q3 EPS by 5c; Boosts FY16 Revenue Outlook

Aralez Pharma (NASDAQ: ARLZ) reported Q3 EPS of ($0.32), $0.05 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $136 million versus the consensus estimate of $12.23 million.

GUIDANCE:

Aralez Pharma sees FY2016 revenue of $54-62 million, versus prior guidance of $48-58 million and the consensus of $47.1 million.

For earnings history and earnings-related data on Aralez Pharma (ARLZ) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c